Drug intelligence / Profile preview

Tanaproget

Development stage: Preclinical
Lead developer: Ligand Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Tanaproget is a non-steroidal small molecule designed as a contraceptive progesterone receptor agonist. It was initially developed by Pfizer and Ligand Pharmaceuticals, with a sublicense granted to an unnamed multinational pharmaceutical company for its worldwide development, registration, and commercialization, particularly in the area of women's health.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on Tanaproget.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanaproget.

Explore the full profile